Abstract 132P
Background
Each decade since 2000, the French College of General Hospital Respiratory Physicians (CPHG) conducts a real-life nationwide prospective epidemiological, observational, multicentre study on primary lung cancer (PLC). First data on patient and tumour characteristics from 2020 cohort are here reported and compared with 2000 and 2010 results.
Methods
Collection of all new PLC histologically or cytologically confirmed between 01/01 and 12/31/2020 in non-academic public hospital pulmonology or oncology units. A Scientific Committee controlled inclusion exhaustivity and quality. These data have been compared to those from KBP-2000 and KBP-2010, conducted according to the same methodology.
Results
82 centres included 8,999 patients (vs 137 and 104 centres; 5,667 and 7,051 patients in 2000 and 2010 respectively). Compared with both previous decades, patients were significantly older (mean age 67.8±10.3 vs65.5 ± 11.3 in 2010 and vs 64.3 ± 11.5 in 2000, P< 0.0001), the proportion of women has increased markedly (34.6% vs 24.3% in 2010 and 16.0 % in 2000, P< 0.0001) and the proportion of non-smokers was also higher (12.6% vs 10.9% in 2010 and 7.2% in 2000, P< 0.0001). Adenocarcinoma was still the main histology (51.9% vs 45.4% in 2010 and 29.0% in 2000, P< 0.0001) and most patients were still in stage IV at diagnosis (60.4%). In 2020, 87.7% of patients benefited from molecular biology testing (vs 30.5% in 2010) and the most frequently observed mutations were KRAS (37.9%), EGFR (14.9%) and STK11 (14.8%). Curative surgery represented 20.3% out of the first therapeutic strategies, radiotherapy 28.6%, chemotherapy 58.4%, targeted therapy 5.8% and immunotherapy 30.2%.
Conclusions
Lung cancer characteristics have evolved during the last 20 years. The patients at diagnosis are older, women’s proportion has significantly increased, non-smokers are more numerous and adenocarcinomas, already predominant in the previous cohort, increase further, molecular biology testing is carried out routinely in real-life setting. KBP-CPHG studies represent a unique data source on lung cancer evolution in France over the last 20 years.
Legal entity responsible for the study
CPHG.
Funding
Multisponsoring study : AstraZeneca, Bayer, Boeringer Ingelheim, Bristol Myers Squibb, Chug, Janssen, MSD, Sanofi, Pfizer, Roche, Takeda, Lilly.
Disclosure
All authors have declared no conflicts of interest.